Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
In HEK-TRPM3 cells, CIM0216 induced a dose-dependent Ca2+ response [pEC50=0.77±0.1 μM], which was not seen in HEK293 cells that were not transfected. In HEK-TRPM3 single-cell FURA2 ratio Ca2+ inference, CIM0216 significantly raises intracellular Ca2+ concentration (1,145±26 nM). In the absence of exogenous Ca2+ or in untransfected HEK cells, these reactions were not seen[1]. CIM0216 (10 μM) did neither stimulate or inhibit TRPM1, TRPM4, TRPM6, or TRPM7 currents. However, it did cause a slight foaming effect when TRPM2 (16.6% foam) and TRPM5 (33.5% foam) were activated. The activation of the human TRPV1 and TRPM8 channels is also not affected by CIM0216 [1].
|
---|---|
References |
Molecular Formula |
C21H21N3O2
|
---|---|
Molecular Weight |
347.410344839096
|
Exact Mass |
347.163
|
CAS # |
1031496-06-6
|
PubChem CID |
42887770
|
Appearance |
White to yellow solid powder
|
Density |
1.3±0.1 g/cm3
|
Boiling Point |
608.7±55.0 °C at 760 mmHg
|
Flash Point |
321.9±31.5 °C
|
Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
Index of Refraction |
1.646
|
LogP |
3.18
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
4
|
Rotatable Bond Count |
4
|
Heavy Atom Count |
26
|
Complexity |
480
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
KSEXDSJYVSEVGF-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C21H21N3O2/c1-15-14-19(23-26-15)22-21(25)20(17-9-3-2-4-10-17)24-13-7-11-16-8-5-6-12-18(16)24/h2-6,8-10,12,14,20H,7,11,13H2,1H3,(H,22,23,25)
|
Chemical Name |
2-(3,4-dihydro-2H-quinolin-1-yl)-N-(5-methyl-1,2-oxazol-3-yl)-2-phenylacetamide
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~35 mg/mL (~100.75 mM)
Ethanol : ~17 mg/mL (~48.93 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8784 mL | 14.3922 mL | 28.7844 mL | |
5 mM | 0.5757 mL | 2.8784 mL | 5.7569 mL | |
10 mM | 0.2878 mL | 1.4392 mL | 2.8784 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.